<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575560</url>
  </required_header>
  <id_info>
    <org_study_id>QCH200501</org_study_id>
    <nct_id>NCT02575560</nct_id>
  </id_info>
  <brief_title>Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>High Dose Weekly Use First-generation EGFR-TKI Instead of Daily Regular Dose in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small
      cell lung cancer with EGFR gene mutation. The median progression free survival time is around
      11 months with the first generation EGFR-TKI. Patients with acquired resistance with first
      generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug
      administration maybe prolong patients PFS and evently prolong OS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1st generation EGFR-TKI has reversible binding to EGFR, it also bind to T790M in a high dose
      which is account about 60% patients acquired resistance to the drug. Resistance patients may
      be benefit to a bolus drug use to block T790M gene.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Time (PFS)</measure>
    <time_frame>an average 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate(ORR)</measure>
    <time_frame>an average half year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time (OS)</measure>
    <time_frame>an average 2 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>EGFR-TKI Resistant Mutation</condition>
  <arm_group>
    <arm_group_label>weekly use erolotinib vs history data</arm_group_label>
    <description>Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>history data</intervention_name>
    <description>history data of PFS after 1st line or second line theray</description>
    <arm_group_label>weekly use erolotinib vs history data</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        histological confirmed local advanced or metastatic lung adenocarcinoma with EGFR mutation
        diagnosed by 2nd generation sequence system.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSCLC with EGFR mutation progressed after first generation EGFR-TKI, or progressed
             after chemotherapy and 1st generation EGFR-TKI or progressed after 1st generation
             EGFR-TKI and chemotherapy. Expected survival more than 3 months with a ECOG â‰¤3.

        Exclusion Criteria:

          -  liver function (ALT, AST) and renal function 2 times higher than normal limit; IPD;
             uncontrolled diarrhea; severe anemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ketao lan</last_name>
    <role>Study Chair</role>
    <affiliation>Qingdao Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qingdao Central Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao Central Hospital</investigator_affiliation>
    <investigator_full_name>Youxin Ji</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Progression-Free Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

